Clinical Trials Insight: 700038891
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2008
At a glance
- Drugs Interleukin-2 (Primary)
- Indications Cancer metastases; Renal cancer
- Focus Registrational; Therapeutic Use
- Sponsors 3SBio
- 18 Nov 2008 New trial record.
- 10 Nov 2008 The company files for the approval of NuLeusin by the Chinese State Food and Drug Administration according to a 3SBio media release.